Interclean Shanghai

Targeting the brain might help patients with respiratory disorders

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

EU Begins Revision of Medical Device...

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical...

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

The brain may be a new therapeutic target for improving breathing following lung injury in COVID-19 patients, according to study in rats

New research published in The Journal of Physiology suggests that lung injury is not limited to the lungs. Targeting the part of the brain that controls breathing and blood flow might help patients with respiratory disorders, such as lung injury due to COVID-19, and speed the process of weaning patients from mechanical ventilators.

With respiratory infections like COVID-19 or other pulmonary infections, activation of the immune system is part of the normal, healthy response. However, in some cases the inflammatory response is so powerful that it leads to further lung damage called acute lung injury (ALI) and in its most severe form acute respiratory distress syndrome (ARDS). Typical clinical care of patients with ALI and ARDS is focused on minimizing further lung damage using specialised forms of mechanical ventilation.

This new study suggests that the injury is not limited to the lungs, but may also have a lasting impact on the central control of respiration. Thus, targeting the parts of the brain that regulate our breathing might be an important therapy for weaning patients from ventilatory support following their recovery from severe respiratory infections, ALI and ARDS. This is important to understand during the COVID-19 pandemic as these patients may experience the same difficulties transitioning to breathing on their own.

Currently, ALI and ARDS therapy focuses on the lungs to maintain gas exchange and minimize further injury.  These researchers examined rats with lung injury and determined that the brain regions that control breathing are affected also. In fact, the characteristics of the pathologic breathing pattern remain even when the lungs are removed. In addition, inflammation was evident in the part of the brain that generates the breathing pattern. This indicates that the lungs are not the only factor involved in breathing disorders in lung injury.

These scientists then examined what happens in conscious lung injured rodents when they introduced non-steroidal anti-inflammatory drugs within the central nervous system. They found that this treatment reduced neural inflammation and minimized the effects of lung injury. These findings suggest that brainstem circuits play a role in the pathophysiology and potential recovery of the respiratory system following lung injury and ARDS.

Commenting on the study, first author Yee-Hsee Hsieh said:

“Clinical treatment for respiratory illnesses typically focuses on adopting ventilatory protocols that protect the lung from further lung injury and current research focuses on repair and restoration of pulmonary tissue and function. This study suggests we also need to address the role of the central nervous system and neuro-inflammation to completely treat acute lung injury and perhaps other lung diseases like COVID-19.”

Latest stories

Related stories

EU Begins Revision of Medical Device Regulatory Framework

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical Devices Regulation

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »